About This Event

LB Pharmaceuticals Inc (Nasdaq: LBRX), visits the Nasdaq MarketSite in Times Square.

LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.

In honor of the occasion, Heather Turner, CEO rings the Closing Bell.